Proactive Investors - Run By Investors For Investors

Arecor fully funded and gearing up to take flagship diabetes drug into clinic

Sarah Howell, chief executive of Arecor, tells Proactive London's Andrew Scott they have a dual business model - there's a technology business where they partner with major pharmaceutical companies, taking their products in-house, apply their technology to deliver back to them an improved product profile and she says that's been very successful .. profitable in its own right and with the upside potential of royalties.

The other side of the business is focused on developing their own portfolio of drugs, initially focused on the diabetes therapeutic area.

''We know that from working with major pharma that we can deliver products that they are unable to develop themselves ... so there is room for a company like Arecor''.

''Ultimately for some of these products for major markets such as insulin we'll look to partner for late stage commercialisation ... so yes we're competing with them but we also see them as partners moving forward''.

Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full ARECO profile View Profile

Arecor Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use